Paul Lee, MD
Family Medicine · Burbank, CANPI 1326042680
Payments from drug & device makers
Across 183 payments — averaging $20.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$433
- GSK$403
- Abbott$311
- AbbVie$266
- Astellas Pharma US Inc$239
- Amgen$213
- plus $2K from 33 others
What the payments were for
- Speaking & faculty fees$40%
- Food & beverage$3,733100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 19 | $433 |
| GSK | 22 | $403 |
| Abbott | 18 | $311 |
| AbbVie | 12 | $266 |
| Astellas Pharma US Inc | 17 | $239 |
| Amgen | 9 | $213 |
| Lilly USA, LLC | 11 | $205 |
| Merz North America, Inc. | 2 | $144 |
| Pfizer | 7 | $135 |
| Novo Nordisk | 8 | $133 |
| Merck | 6 | $121 |
| AstraZeneca | 6 | $102 |
| Sanofi-aventis U.S. LLC | 5 | $92 |
| Hologic Sales And Service, LLC | 3 | $86 |
| Novartis | 4 | $85 |
| Exact Sciences | 3 | $65 |
| Shockwave Medical, Inc | 1 | $55 |
| Kowa Pharmaceuticals America, Inc. | 2 | $50 |
| Johnson & Johnson | 2 | $47 |
| Phadia US Inc. | 3 | $46 |
| Sumitomo Pharma America, Inc. | 2 | $44 |
| Gilead | 2 | $42 |
| Endogastric Solutions, Inc | 1 | $38 |
| Sanofi Pasteur Inc. | 2 | $37 |
| Pacira Pharmaceuticals Incorporated | 1 | $34 |
| Eisai Inc. | 2 | $32 |
| Otsuka America Pharmaceutical, Inc. | 1 | $31 |
| Teva Pharmaceuticals USA, Inc. | 1 | $28 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $25 |
| Stryker | 1 | $25 |
| Almatica Pharma LLC | 1 | $24 |
| Regeneron Healthcare Solutions, Inc. | 1 | $23 |
| Dynavax Technologies Corporation | 1 | $21 |
| Biohaven Pharmaceuticals, Inc. | 1 | $20 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $19 |
| Mayne Pharma Commercial LLC | 1 | $18 |
| Xeris Pharmaceuticals, Inc. | 1 | $17 |
| Cequr Corporation | 1 | $15 |
| Linus Health, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XEOMIN$140
How this compares
$3,737 in reported general payments places this provider in the 85th percentile of 10,533 family medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JanuviaSitagliptin Phosphate | 35 | $56,487 |
| JardianceEmpagliflozin | 47 | $50,631 |
| RybelsusSemaglutide | 20 | $39,670 |
| EliquisApixaban | 31 | $38,248 |
| OzempicSemaglutide | 33 | $37,535 |
| XareltoRivaroxaban | 14 | $23,767 |
| FarxigaDapagliflozin Propanediol | 25 | $22,340 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 15 | $18,086 |
| MounjaroTirzepatide | 11 | $12,834 |
| TrulicityDulaglutide | 13 | $12,044 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 17 | $8,685 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 11 | $4,954 |
| Atorvastatin Calcium | 410 | $3,744 |
| Tamsulosin Hcl | 186 | $2,940 |
| Levothyroxine Sodium | 207 | $2,907 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskRybelsus, Ozempic | $133 | $77,20453 claims |
| MerckJanuvia | $121 | $56,48735 claims |
| Boehringer IngelheimJardiance | $433 | $50,63147 claims |
| PfizerEliquis | $135 | $38,24831 claims |
| Lilly USA, LLCMounjaro, Trulicity | $205 | $24,87824 claims |
| Johnson & JohnsonXarelto | $47 | $23,76714 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $403 | $23,04026 claims |
| AstraZenecaFarxiga | $102 | $22,34025 claims |
| AbbVieSynthroid | $266 | $2,01919 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 10,533 family medicine providers in California.
Other family medicine in Burbank
- Amina HaggagNorthridge$112.8M
- Steven ReynoldsLong Beach$53M
- Rizwana MohseniLake Forest$26.7M
- Daniel JohnsonSan Diego$15.7M
- Stacey LayleSan Diego$14.8M
- Apinya VutikullirdCypress$14.3M
- Hanid AudishSpring Valley$13.6M
- Augusto FocilOxnard$12.6M
- Jack VuLong Beach$10.1M
- Suzanne FussellOxnard$8.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.